Accessibility

LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Microarray-Products of Conception (POC) Reveal® FFPE

CPT: 81229
Updated on 09/23/2020
Print Share

Synonyms

  • aCGH
  • CGH
  • CMA
  • Microarray
  • Reveal® SNP Microarray-Products of Conception (POC)
  • SNP Array
  • WGA

Special Instructions

Pertinent medical findings should accompany the test request form. Please direct questions to genetic customer service at 800-345-4363.

There may be an additional charge for formalin positive tissue samples requiring embedding and pathology.


Expected Turnaround Time

14 - 21 days


Related Documents


Specimen Requirements


Specimen

Preferred fixed products of conception (POC), formalin-fixed paraffin-embedded (FFPE) tissue


Volume

One paraffin block or ten 10-micron thick section slides


Minimum Volume

Extracted DNA from received specimen must yield at least 10 ul at a concentration of 8 ng/ul.


Container

Paraffin block transport pouch


Collection

Specimen should be fixed in 10% neutral-buffered formalin or formaldehyde.


Storage Instructions

Room temperature


Causes for Rejection

No fetal visualized on pathology report; only a small area is identified on fixed sample as fetal, and is less than 50% of sample


Test Details


Use

This test will detect chromosomal imbalance that could be associated with developmental delay/congenital anomalies. It provides detection of possible uniparental disomy of any chromosome, the percent and location of homozygosity, including the degree of identity by descent. It will also allow the detection of complete or partial molar pregnancies.

This test will detect chromosomal imbalance that could be associated with developmental delay/congenital anomalies.It provides detection of uniparental disomy of any chromosome, the percent and location of homozygosity, including the degree of identity by descent.It will also allow the detection of complete or partial molar pregnancies.

This test will detect chromosomal imbalance that could be associated with developmental delay/congenital anomalies. It provides detection of possible uniparental disomy of any chromosome, the percent and location of homozygosity, including the degree of identity by descent. It will also allow the detection of complete or partial molar pregnancies.


Limitations

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only contain heterochromatin or tetraploidy. Genotypes in some formalin-fixed tissues are unable to be determined, allowing only genomic dosage to be determined.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only contain heterochromatin, or tetraploidy. Genotypes in some formalin-fixed tissues are unable to be determined, allowing only genomic dosage to be determined.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only contain heterochromatin or tetraploidy. Genotypes in some formalin-fixed tissues are unable to be determined, allowing only genomic dosage to be determined.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.


Methodology

SNP Microarray analysis is performed using the Oncoscan® FFPE platform, which uses more than 220,000 SNP probes with a median spacing of 5.0kb, within the majority of genes.

SNP Microarray analysis is performed using the Oncoscan® FFPE platform, which uses more than 220,000 SNP probes with a median spacing of 5.0kb, within the majority of genes.

SNP Microarray analysis is performed using the Oncoscan® FFPE platform, which uses more than 220,000 SNP probes with a median spacing of 5.0kb, within the majority of genes.

SNP Microarray analysis is performed using the Oncoscan® FFPE platform, which uses more than 220,000 SNP probes with a median spacing of 5.0kb, within the majority of genes.

SNP Microarray analysis is performed using the Oncoscan® FFPE platform, which uses more than 220,000 SNP probes with a median spacing of 5.0kb, within the majority of genes.


References

Wang Y, Cheng Q, Meng L, et al. Clinical application of SNP array analysis in first-trimester pregnancy loss: a prospective study. Clin Genet. 2017 Jun;91(6):849-858.27883173

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
511997 Reveal(R) POC Paraffin 94087-4 511998 Specimen Type 48002-0
511997 Reveal(R) POC Paraffin 94087-4 511999 # of Genotyping Targets N/A
511997 Reveal(R) POC Paraffin 94087-4 512000 Array Type 62377-7
511997 Reveal(R) POC Paraffin 94087-4 512001 Diagnosis 62357-9
511997 Reveal(R) POC Paraffin 94087-4 512002 Interpretation 62373-6
511997 Reveal(R) POC Paraffin 94087-4 512003 Director Review 48672-0
511997 Reveal(R) POC Paraffin 94087-4 512123 PDF 51967-8

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf